IGF1R and small cell lung carcinoma: IGF-1R has been described as an essential kinase in the SCLC-P subgroup, and IGF-1R inhibitor (linsitinib) treatment has shown significant antiproliferative effect on SCLC cell lines with high POU2F3 expression (SCLC-P subtype) [68].